Capsule & Omics for pRedicting Exacerbation of Crohn's Disease - Trial NCT06362174
Access comprehensive clinical trial information for NCT06362174 through Pure Global AI's free database. This phase not specified trial is sponsored by Sheba Medical Center and is currently Recruitment Completed. The study focuses on Crohn's Disease. Target enrollment is 62 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Observational
Sponsor & Location
Sheba Medical Center
Timeline & Enrollment
N/A
Feb 07, 2023
Dec 31, 2025
Primary Outcome
Crohn's Disease Activity Index score (CDAI),Disease related complications,disease related hospitalization,Change of crohn's disease medications,opinion of the principle investigator (PI) or the treating physician
Summary
The research group have previously evaluated the benefit of serial consecutive capsule
 endoscopy as monitoring tool for Crohn's disease in remission, demonstrating its superior
 accuracy for disclosing inflammation and for prediction of flares in comparison to other
 diagnostic modalities such as magnetic resonance enterography and inflammatory biomarkers.
 Subsequently, deep learning algorithms had developed to provide excellent accuracy for
 identification and grading of ulcers and intestinal strictures on capsule endoscopy still
 images. The investigators will advance this knowledge using a parallel two-parts approach.
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT06362174
Non-Device Trial